London’s Hammersmith Hospital, part of the Imperial College Healthcare NHS Trust, is host to the clinical trial started on Vectorious’ wireless, in heart microcomputer, V-LAP. The new device is inserted into the heart’s left atrium and collects data on the fluctuations in pressure in a patient’s heart which is sent to doctors via a chest strap which also charges the sensor remotely. The developers hope that instead of relying on physiological symptoms to appear at a later stage of heart disease, doctors will be able to adapt treatment plans for patients based on the daily analysis collected from the device, therefore reducing the need for hospital admission, making huge savings for the NHS, while improving quality of life for patients.
Consultant cardiologist from Imperial College Healthcare NHS Trust, Dr Zachary Whinnett, stated: “The V-LAP device promises to provide a significant step forward in the management of people with heart failure. Heart failure is usually a chronic heart condition, which can cause a high symptom burden and often requires frequent admissions to hospital. The V-LAP device provides remote daily monitoring of clinical status as it directly measures pressure within the heart. The aim is to be able to tailor treatment to the individual person so that we can make changes in treatment at an early stage in order to prevent worsening symptoms and hospital admissions.”
“V-LAP enters clinical trial. “
CEO of Vectorious, Oren Goldshtein, stated: “We believe the V-LAP sensor represents a real step change in the treatment of heart disease for the 1 million people living with heart failure in the UK. Since the pressure of the heart’s left atrium is the earliest and most accurate real-time indication of heart failure exacerbation, the feedback provided by the V-LAP will enable a significant improvement in ongoing management of these patients. It will enable doctors to adjust the patient’s medication early enough, often remotely, and as a result avoid their condition worsening and a re-admission into hospital. By having individual, long-term data for each patient, doctors will be able to react to each individual, rather than resorting to what often amounts to guess work and estimations that are currently the case. We are excited about extending our study in the UK and would encourage existing patients to contact Hammersmith Hospital in London and Queen Elizabeth hospital in Birmingham to see if they could be enrolled.”